BIOMATICS MANAGEMENT COMPANY, LLC

Thesis

Biomatics Capital Partners, a venture capital firm established in 2016 and based in Seattle, Washington, focuses on investing in transformative, data-driven innovations within the healthcare and technology sectors. Their core investment thesis posits that data will revolutionize healthcare, similar to its impact on other industries. They target companies developing breakthroughs in diagnostics, therapeutics, research and development, and clinical care, with specific interests in gene editing, DNA synthesis, digital health, medical technology, and proteomics. Biomatics Capital seeks to identify and support 'outlier' companies with disruptive potential that can improve patient outcomes and reduce costs, particularly those leveraging the convergence of genomics and digital data. The firm primarily invests in early-stage companies (seed, Series A, Series B) but is open to later-stage rounds. They operate mainly in North America, with a strong focus on the United States, and have a presence in Boston, Massachusetts. The firm has managed significant capital through its funds, including Fund I ($200 million, closed 2017) and Fund II ($300 million, launched 2018). Initial investments typically range from $5 million to $10 million, with potential for up to $30 million over the investment lifecycle. They often act as a Series A lead investor. Notably, the firm has stated it is fully committed and no longer investing in new opportunities.